文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

COVID-19疫情期间临床试验参与趋势:I-SPY COVID临床试验的二次分析

Trend in Clinical Trial Participation During COVID-19: A Secondary Analysis of the I-SPY COVID Clinical Trial.
PubMed 文献 · Crit Care Explor · 2023-06-19
一句话结论在I-SPY COVID试验中,随时间推移及疫苗接种状态不同,入组率无显著差异,年龄、性别、居住地区、病情严重程度和疫苗接种状态与拒绝同意无关。

本文为I-SPY COVID随机对照试验的二次分析,旨在分析美国COVID-19大流行前三波期间平台试验入组率的时间趋势。研究纳入2020年7月30日至2022年2月17日期间被接触邀请参加I-SPY COVID试验的1338例患者,其中入组1063例,拒绝275例,计算每月入组率。结果显示入组率随时间波动但无显著趋势(Mann-Kendall检验,p=0.21),疫苗接种者与未接种者入组率相当,多因素logistic回归显示年龄、性别、居住地区、COVID-19疾病严重程度和疫苗接种状态与拒绝同意无显著关联。作者认为需进一步研究以理解大流行是否改变了临床试验参与并制定策略鼓励未来参与。

要点

  • 2020年7月30日至2022年2月17日期间,共1338例患者被接触邀请参加I-SPY COVID试验,其中1063例入组,275例拒绝。
  • 入组率在COVID-19大流行期间波动,但无显著时间趋势(Mann-Kendall检验,p=0.21)。
  • 疫苗接种者与未接种者的入组率相当。
  • 多因素logistic回归分析显示,年龄、性别、居住地区、COVID-19疾病严重程度和疫苗接种状态与拒绝同意的决定无显著关联。
  • 入组与拒绝参与的患者在人口学和基线临床特征上总体相似。

适用人群与场景

  • 2020年7月30日至2022年2月17日期间,在美国31家医院被直接或通过合法授权代表接触邀请同意并入组I-SPY COVID随机对照试验的患者。

研究设计与关键结果

  • 研究类型:I-SPY COVID随机对照试验数据的二次分析;场所:美国31家医院;人群:被接触邀请参加I-SPY COVID试验的患者。
  • 共1338例患者被接触邀请,其中入组1063例,拒绝参与275例,用于计算每月入组率。
  • 入组与拒绝参与的患者在人口学和基线临床特征上总体相似。
  • 入组率在COVID-19大流行期间波动,但无显著时间趋势(Mann-Kendall检验,p=0.21)。
  • 疫苗接种者与未接种者的入组率相当。
  • 多因素logistic回归分析显示,年龄、性别、居住地区、COVID-19疾病严重程度和疫苗接种状态与拒绝同意的决定无显著关联。

证据类型、等级与局限

  • 证据类型:随机对照试验的二次分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 原文结论未据此给出推荐;作者认为需要额外研究以更好地理解COVID-19大流行是否改变了临床试验参与,并制定策略鼓励参与未来的COVID-19和重症临床试验。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

UNLABELLED: To analyze the temporal trend in enrollment rates in a COVID-19 platform trial during the first three waves of the pandemic in the United States.

DESIGN: Secondary analysis of data from the I-SPY COVID randomized controlled trial (RCT).

SETTING: Thirty-one hospitals throughout the United States.

PATIENTS: Patients who were approached, either directly or via a legally authorized representative, for consent and enrollment into the I-SPY COVID RCT.

INTERVENTIONS: None.

MEASUREMENTS AND MAIN RESULTS: Among 1,338 patients approached for the I-SPY COVID trial from July 30, 2020, to February 17, 2022, the number of patients who enrolled (n = 1,063) versus declined participation (n = 275) was used to calculate monthly enrollment rates. Overall, demographic and baseline clinical characteristics were similar between those who enrolled versus declined. Enrollment rates fluctuated over the course of the COVID-19 pandemic, but there were no significant trends over time (Mann-Kendall test, p = 0.21). Enrollment rates were also comparable between vaccinated and unvaccinated patients. In multivariable logistic regression analysis, age, sex, region of residence, COVID-19 severity of illness, and vaccination status were not significantly associated with the decision to decline consent.

CONCLUSIONS: In this secondary analysis of the I-SPY COVID clinical trial, there was no significant association between the enrollment rate and time period or vaccination status among all eligible patients approached for clinical trial participation. Additional studies are needed to better understand whether the COVID-19 pandemic has altered clinical trial participation and to develop strategies for encouraging participation in future COVID-19 and critical care clinical trials.

来源:Crit Care Explor,查看原文。版权归原作者所有。

参考来源

  1. Yang P, Dickert NW, Haczku A, et al. Trend in Clinical Trial Participation During COVID-19: A Secondary Analysis of the I-SPY COVID Clinical Trial. Crit Care Explor. 2023. PMID: 37346229. doi:10.1097/CCE.0000000000000930

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。